Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

Ian H. de Boer, M. Luiza Caramori, Juliana C.N. Chan, Hiddo J.L. Heerspink, Clint Hurst, Kamlesh Khunti, Adrian Liew, Erin D. Michos, Sankar D. Navaneethan, Wasiu A. Olowu, Tami Sadusky, Nikhil Tandon, Katherine R. Tuttle, Christoph Wanner, Katy G. Wilkens, Sophia Zoungas, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin HowellMarcello Tonelli, Michael Cheung, Amy Earley, Peter Rossing

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.

Original languageEnglish
Pages (from-to)839-848
Number of pages10
JournalKidney International
Volume98
Issue number4
DOIs
Publication statusPublished - Oct 2020

Keywords

  • angiotensin II receptor blocker
  • angiotensin-convering enzyme inhibitor
  • chronic kidney disease
  • dialysis
  • evidence-based
  • GLP-1 receptor agonist
  • glycemia
  • glycemic monitoring
  • glycemic targets
  • guideline
  • HbA1c
  • hemodialysis
  • KDIGO
  • lifestyle
  • metformin
  • models of care
  • nutrition
  • renin-angiotensin system
  • self-management
  • SGLT2 inhibitor
  • systematic review
  • team-based care

Fingerprint

Dive into the research topics of 'Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment'. Together they form a unique fingerprint.

Cite this